Adding an anti-obesity medication just one month after behavioural therapy begins - rather than waiting the currently recommended six months - can more than double weight loss for patients who struggle initially with lifestyle changes alone, according to researchers at the Perelman School of Medicine at the University of Pennsylvania.
Both behavioural therapy and anti-obesity medications can help patients to succeed in meeting their weight and health goals. However, the effectiveness of these treatments varies widely for different individuals. This research addresses a critical gap by providing evidence that people who struggle to lose weight with one treatment method can succeed when a different kind of treatment is added.
Most obesity management guidelines recommend trying behavioural interventions for at least six months as the first-line treatment for individuals who could benefit from weight loss. These lifestyle interventions include a reduced-calorie diet, increased physical activity and behavioural strategies (like tracking food intake and physical activity).
The sessions are led by trained counsellors and focus on helping participants set specific, achievable health and weight goals. They also provide accountability and feedback on goals from the previous week. However, previous research has shown that up to half of patients do not achieve a clinically meaningful loss of at least 5% of their starting weight with these tactics.
"Surprisingly little is known about how to help patients who struggle to lose weight when they are already receiving frequent lifestyle counselling sessions," said Dr Jena Shaw Tronieri, a Senior Research Investigator at the Center for Weight and Eating Disorders in the Department of Psychiatry. "Some experts have suggested that adding an anti-obesity medication should be the next step, but no studies have tested whether this approach actually improves weight loss."
The study, led by Tronieri, evaluated an early intervention approach for patients who lost less than 2% of their initial body weight after a month of weekly behavioural sessions (less than one pound per week for most patients). These early non-responders to behavioural treatment were randomly assigned to take either the anti-obesity medication phentermine hydrochloride (15.0mg per day) or a placebo while they completed 24 more weeks of behavioural intervention. Phentermine, an appetite suppressant, is the oldest weight-loss drug currently on the market and was first approved by the FDA in 1959.
Study participants who took a placebo along with the one-on-one sessions lost only 2.8% of their starting weight after 24 weeks. However, for participants who added phentermine, weight loss more than doubled to 5.9% of their starting weight. For context, a person weighing 250lbs would lose approximately 15lbs with the added medication compared to only about 7lbs with behavioural therapy plus placebo.
Meanwhile, those who responded well from the start of the behavioural sessions - called "early strong responders" - continued without medication and lost an additional 5.1% of their starting weight over the same six-month period.
"Our results strongly support the addition of anti-obesity medications for patients who do not achieve meaningful weight loss with behavioural methods alone," said Tronieri. "They also suggest that the medication can be introduced early in treatment, rather than waiting until a patient completes a full six-month programme. Early intervention is crucial because patients who don't see initial results are more likely to become discouraged and discontinue treatment altogether."
The researchers hope that the treatment used in this study will provide a road map for health professionals looking to support patients who find it hard to lose weight with diet and exercise alone. However, the efficacy of other FDA-approved weight-loss medications for patients who do not lose significant weight with behavioural methods still needs to be established through formal testing.
"If the people who were early non-responders took one of the newer approved medications, like semaglutide or tirzepatide, it's likely they could easily double or triple their weight loss compared to phentermine," said study co-author, Dr Thomas A Wadden, a professor of Psychology in Psychiatry. "Additional research is needed to confirm this hypothesis."
The findings were reported in the paper, ‘Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial’, published in Nature Medicine. To access this paper, please click here
Commentaires